|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants
To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in healthy volunteers
100 Clinical Results associated with NGFB x TLR4
100 Translational Medicine associated with NGFB x TLR4
0 Patents (Medical) associated with NGFB x TLR4